The 22nd JFCR-ISCC
New Antitumor Agents under Development in the US, Europe and Japan

**December 13 (Wed) 13:00 -19:00**

- **Session 1**
  - 13:10 -
  - Genetic biomarkers and rational combinations for cancer immunotherapy
    - Scott K. Pruitt, Merck Research Laboratories
      - The first tumor-type agnostic regulatory approval: Pembrolizumab for the treatment of advanced MSI-H/dMMR cancer
    - Philip J. Stephens, Foundation Medicine
      - Identification of novel modulators of response to immune checkpoint blockade in lung cancer patients through the marrying of clinical and genomic data

**December 14 (Thu) 9:00 -18:30**

- **Session 2**
  - 15:00 -
  - Sophisticated DNA damage inducers for cancer therapy
    - Yves G. Pommier, NCI, NIH
      - PARP trapping and replicative damages
      - Targeting the Achilles’ heel of cancer: Sequence specific alkylation at KRAS driver gene DNA mutations

**2017**

**Miraikan**
National Museum of Emerging Science and Innovation
2-3-6, Aomi, Koto-ku, Tokyo, Japan

**Contact:** Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
jfcr-isc@ml.jfcr.or.jp
http://iscc.umin.jp/